^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | HERtiCAD (trastuzumab biosimilar) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The effectiveness, safety and economic rationality of the neoadjuvant chemotherapy with biosimilar of Trastuzumab in HER2+ breast cancer in Russian clinical practice.
Published date:
05/16/2018
Excerpt:
...biosimilar of trastuzumab (BT) in the neoadjuvant chemotherapy in HER2+ breast cancer (BC)...The rate of pCR was 55,6% (breast) and 45,8% (breast and lymph nodes). The rate of pCR was the same in women with primary-operable and locally-advance stages (58,6 vs 52%, p = 0,625), as well as in luminal and non-luminal BC (54,2 vs 56,7%, p = 0,854)...Neoadjuvant chemotherapy with BT was effective...
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.2018.36.15_suppl.e12656
